Device Trial Radar · NCT07844434
AI-Based Cardiac Analysis Using 12-Lead and 1-Lead ECG
Last checked: Nov 20, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
300
Planned (sponsor's estimate)
Start
Nov 10, 2026
Primary completion
Aug 30, 2027
Study completion Mar 30, 2028
Sponsor
- Lead sponsor
- Inha University HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 28, 2026
Design
- Study type
- Observational
- FDA-regulated device
- No
- Who can join
- All sexes, from 19 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This pilot study is designed to evaluate the clinical performance and utility of the SmartECG-EF software in patients undergoing evaluations at Inha University Hospital. The primary objective is to assess how effectively the device assists clinicians in evaluating cardiac function and related clinical parameters. The study will prospectively enroll eligible participants to gather real-world clinical data, contributing to enhanced diagnostic accuracy and patient management.
Conditions
- Heart Failure
- Atrial Fibrillation (AF)
- Electrocardiogram
Interventions
SmartECG-EFDevice
The SmartECG-EF software is used to analyze 12-lead and 1-lead electrocardiogram (ECG) data to evaluate cardiac function, including left ventricular systolic dysfunction (LVSD), heart failure indicators, and related arrhythmic parameters.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Correlation and Agreement between 12-Lead and 1-Lead AI ScoresTime frame: Day 1
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Inha University Hospital
Incheon, Incheon, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.